HIV, Hepatitis & COVID Antivirals — Philippines, South Africa, Australia & Singapore | Unnati Pharma

❓ FAQ 1: How does South Africa's differentiated service delivery (DSD) model for HIV treatment connect to affordable generic supply like Unnati Pharmax's range?

South Africa's National Department of Health has implemented Differentiated Service Delivery (DSD) — a model that provides stable, virally suppressed HIV-positive patients with 3-6 months of antiretroviral supply in a single pickup, reducing clinic burden and enabling patients to manage their own treatment with minimal facility contact. DSD models include: Community Adherence Groups (CAGs) where small groups of stable patients rotate clinic attendance and share medication collection for each other; Fast Lane services providing quick pick-up for stable patients; and Medication Adherence Clubs serving groups collectively. This DSD framework dramatically reduces treatment burden — particularly important for South Africa's working HIV-positive population who cannot afford frequent clinic absence. For South Africa's private sector (approximately 20% of the population), where DSD doesn't apply and patients pay for private prescription medications, Unnati Pharmax's Spegra, Tafero EM, and Generic Biktarvy provide affordable alternatives to South African private pharmacy brand pricing that can exceed ZAR 3,000-5,000 monthly for branded antiretrovirals — a cost that even middle-income South Africans struggle to sustain long-term.

❓ FAQ 2: How does the Philippines' PhilHealth system cover HIV treatment and where do Unnati Pharmax's products fit?

The Philippines' PhilHealth (national health insurance) has expanded HIV-related coverage in recent years — the HIV/AIDS treatment programme provides antiretrovirals through Treatment Hubs at government hospitals (Philippine General Hospital, San Lazaro Hospital, and regional treatment hubs) at no cost to enrolled HIV-positive patients. However, significant access gaps remain: Social Hygiene Clinics and Treatment Hubs are concentrated in Metro Manila and provincial capitals, leaving rural and island province residents with limited access; stigma prevents many HIV-positive Filipinos from attending government HIV clinics where their status may become known in small communities; drug supply disruptions at government hubs have been documented; and patients not formally enrolled in the government programme (recent diagnoses awaiting enrollment, those who prefer private care) face full private cost. For Filipino HIV-positive individuals outside the government programme — particularly professionals, business owners, and OFW returnees who prefer private, discreet treatment — Unnati Pharmax's Spegra and Generic Biktarvy at dramatically reduced private cost provide quality-certified affordable treatment without requiring government programme enrolment.

❓ FAQ 3: How does Singapore's sophisticated healthcare approach to HIV — with its comprehensive government HAART programme — interact with Unnati Pharmax's market?

Singapore has one of Asia-Pacific's most comprehensive HIV management programmes — the National HIV Programme provides antiretroviral treatment at Communicable Disease Centre and DSC Clinic at discounted rates for eligible Singapore citizens and permanent residents. HIV-positive Singapore residents on long-term suppressive ART pay a subsidised rate at government facilities — significantly less than private healthcare pricing. However, Singapore's HIV-positive community still benefits from Unnati Pharmax access in specific situations: non-citizen, non-PR Singapore residents (employment pass holders, dependant pass holders from countries with HIV stigma) who prefer completely private treatment outside Singapore government health systems; patients wanting to supplement their government regimen with a specific formulation not available at subsidised rates; and Singapore's significant Indonesian, Malaysian, and other ASEAN community members managing HIV without permanent residency. Singapore's high digital literacy and health awareness means customers are exceptionally well-informed — they specifically research WHO-GMP certification, bioequivalence data, and manufacturing standards before purchasing — making Unnati Pharmax's transparent documentation approach particularly valued in this market.

❓ FAQ 4: What is the latest evidence on HIV cure research and what does it mean for patients in these four markets currently on Unnati Pharmax antivirals?

HIV cure research has achieved remarkable milestones in recent years — several individuals have achieved functional cure through stem cell transplantation (the "Berlin Patient," "London Patient," "City of Hope Patient") using donor cells with the CCR5-Δ32 mutation that prevents HIV entry. However, stem cell transplantation carries substantial mortality risk and is only justifiable for patients requiring transplant for other indications (leukaemia). Broadly accessible cure approaches — gene therapy, latency reversal ("shock and kill"), immunotherapy — remain in early-to-mid clinical trials. The realistic timeline for a widely accessible HIV cure: most experts project 10-15+ years before any approach reaches broad clinical availability at affordable global scale. For patients in the Philippines, South Africa, Australia, and Singapore currently using Unnati Pharmax antivirals: today's Dolutegravir-based regimens (Spegra) and Bictegravir-based regimens (Generic Biktarvy) are so safe, tolerable, and effective that they enable near-normal life expectancy — making the gap to functional cure a manageable clinical interval rather than an existential threat. Maintaining viral suppression today is the foundation for being alive and healthy when cure becomes accessible.

❓ FAQ 5: What new antiviral products is Unnati Pharmax planning to add to its range for these four markets in 2026-2027?

Unnati Pharmax continuously evaluates its antiviral range to meet evolving clinical needs across our markets. Current planning for 2026-2027 additions: pan-genotypic HCV combination (Sofosbuvir+Velpatasvir) for HCV Genotype 2 and 3 patients in our markets who need an alternative to Resof L's Genotype 1 primary indication; Dolutegravir/Lamivudine two-drug regimen (2DR) for virologically stable HIV patients where a simplified two-drug maintenance regimen is appropriate; and updated COVID antiviral options as the antiviral landscape for SARS-CoV-2 continues evolving with new variant emergence. We evaluate new products against strict criteria: WHO-GMP certification from an accredited manufacturer; phase III clinical trial evidence supporting the indication; regulatory approval in major reference markets (US FDA, EMA, TGA); and a clear unmet access need in our markets where current pricing creates barriers. Our customers in the Philippines, South Africa, Australia, and Singapore are directly surveyed through our WhatsApp community for product needs — your feedback through Unnatipharmax@gmail.com or +91 82650 41513 directly influences our product range development. Visit unnatipharmax.com for current product listings and announcements of new additions.